A.E. Pozdnyakova Post-graduate Student, Department of Pharmaceutical Technology with Medical Biotechnology Course, Pyatigorsk Medical and Pharmaceutical Institute E-mail: Z.D. Khadzieva Dr.Sc. (Pharm.), Professor, Department of Pharmaceutical Technology with Medical Biotechnology Course, Pyatigorsk Medical and Pharmaceutical Institute E-mail: N.S. Zagorskaya Post-graduate Student, Department of Pharmaceutical Technology with Medical Biotechnology Course, Pyatigorsk Medical and Pharmaceutical Institute E-mail: D.I. Pozdnyakov Ph.D. (Pharm.), Head of living System Laboratory, Senior Lecturer of Department of Pharmacology with Clinical Pharmacology Course, Pyatigorsk Medical and Pharmaceutical Institute

The aim of the study: to evaluate the anti-allergic properties of the new combined nasal spray in experiment. Materials and methods: the study was performed on 70 male mice of the BALB/c line, which reproduced ovalbumin-induced allergic rhinitis. The animals were immunized for 14 days, after that they provoked acute rhinitis by intranasal administration of ovalbumin. Further, blood sampling was performed in mice with subsequent serum and determination of the concentration of proallergic markers: histamine, IFN-γ, IL-6, IgE and TNF-α by ELISA. The test-spray in doses of 2.5; 5 and 7.5 μ/nostril and the reference drugs levocabastine at a dose of 5 μ /nostril and beclomethasone in the dose of 3.5 μ /nostril was administred intranasally 30 min before provocation of acute allergic rhinitis. Results: when administered to the animals of the test-spray in doses of 2.5, 5 and 7.5 µg/nostril, a decrease in the severity of the allergic reaction in mice with experimental allergic rhinitis was noted, which may be evidenced by a decrease in serum concentrations of histamine, IFN-γ, IL-6, IgE, and TNF-α. At the same time, against the background of intranasal administration of the test-spray at a dose of 5 µg/nostril, the content of histamine, IFN-γ, IL-6, IgE, and TNF-α in serum decreased by 69.1% (p

anti-allergic drugs
allergic rhinitis
ammonium glycirizinate

  1. Dykewicz M.S., Hamilos D.L. Rhinitis and sinusitis // J Allergy Clin Immunol. 2010;125: 103–S115. doi: 10.1016/j.jaci.2009.12.989.
  2. World Health Organization [internet]. Global Surveillance, preven-tion and control of Chronic Respiratory Diseases: A
  3. Comprehensive approach 2007. [Lase accessed on 2018 Dec 22]. Available from: .
  4. Poddighe D., Licari A., Caimmi S., Marseglia G.L. Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence // World J Clin Pediatr. 2016;5(1):47–56. doi:10.5409/wjcp.v5.i1.47.
  5. Kim S.H., Won H.K., Moon S.D. Impact of self-reported symptoms of allergic rhinitis and asthma on sleep disordered breathing and sleep disturbances in the elderly with polysomnography study // PLoS One. 2017;12(2):e0173075. doi:10.1371/journal.pone.0173075
  6. Wilhelm C.P., deShazo R.D., Tamanna S., Ullah M.I., Skipworth L.B. The nose, upper airway, and obstructive sleep apnea. ANAI. 2015;115(2):96–102.
  7. Wheatley L.M., Togias A. Allergic rhinitis // N Engl J Med. 2015; 372(5):456–63.
  8. Prasad B., Nyenhuis S.M., Weaver T.E. Obstructive sleep apnea and asthma: associations and treatment implications. Sl. med. rev. 2014;18(2):165–71. doi: 10.1016/j.smrv.2013.04.004.
  9. Yanez A., Rodrigo G.J. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systemat-ic review with meta-analysis // Ann Allergy Asthma Immunol. 2002; 89(5):479–484. doi: 10.1016/S1081-1206(10)62085-6.
  10. Allen D.B., Meltzer E.O., Lemanske R.F., Philpot E.E., Faris M.A., Kral K.M., Prillaman B.A., Rickard K.A. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year // Allergy Asthma Proc. 2002; 23(6):407–413.
  11. Yilmaz Sahin A.A., Corey J.P. Rhinitis in the elderly // Curr Allergy Asthma Rep. 2006;6:125–131. doi: 10.1007/s11882-006-0050-3.
  12. Lee T.A., Pickard A.S. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy. 2007; 27:852–9.
  13. Rudack C. Actual therapeutic management of allergic and hyperre-active nasal disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2004; 3:Doc04.
  14. Tonelli L.H., Katz M., Kovacsics C.E. et al. Allergic rhinitis induc-es anxiety-like behavior and altered social interaction in rodents // Brain Behav Immun. 2009; 23(6):784–93.
  15. Mösges R., Spaeth J., Klimek L. Efficacy and tolerability of levoca-bastine and azelastine nasal sprays for the treatment of allergic rhini-tis. Mediators Inflamm. 1995;4(7):S11–5.
  16. Li Q., Zhang Y.D., Sun C.W., Chen Y.L., Du Y.H., Zhao G.J., & Zhang D.L. Treatment of allergic rhinitis rats by intranasal interfer-on gamma. Chinese j. otorhinol. head neck surg.-2008, 43(2), 134–138